Other

University of Texas System

National Institutes of Health, a Component of the US Dept. of Health & Human Services

The Scripps Research Institute

The Administrators of the Tulane Educational Fund

Zalgen Labs, LLC

US Government As Represented by the Secretary of the Army

Thomas W Geisbert

Ian MacLachlan

Lisa E Hensley

Vandana Sood

Gary J Nabel

Robert F Garry

Adam Judge

Nancy J Sullivan

Amy C H Lee

James E Robinson

Marjorie Ann Robbins

Peter B Jahrling

Erica Ollmann Saphire

Robert W Cross

Chad E Mire

Kathryn M Hastie

Luis Manuel Branco

Elliott Kagan

Luis M Branco

Sergio E Rodriguez

Joan B Geisbert

Disclosed herein are compositions comprising recombinant arenavirus monoclonal antibodies and antigen-binding fragments thereof, as well as therapeutic methods using the antibodies. In some embodiments, the antibodies provide pan-arenavirus protection against a number of arenavirus types and strains.

Arena virus monoclonal antibodies and uses

Certain embodiments are directed generally to compositions and methods related to recombinant vesicular stomatitis virus vectors (&#x394;GrVSV) encoding Crimean-Congo Hemorrhagic Fever glycoprotein precursor (CCHFV-GPC) and forming a recombinant vesicular stomatitis virus vector encoding Crimean-Congo Hemorrhagic Fever glycoprotein precursor (&#x394;GrVSV-CCHFV-GPC).

Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen

Disclosed herein are compositions comprising arenavirus monoclonal antibodies, as well as therapeutic, diagnostic, and preventative methods using the novel antibodies. Preventative methods include preparation of vaccines, as well as factors (e.g. small molecules, peptides) that inhibit Old World arenavirus infectivity, including LASV and LCMV. In some embodiments, the antibodies provide pan-arenavirus protection against a number of arenavirus types and strains. Diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses are also disclosed, as well as new tools and methods for the design, production, and use of arenavirus monoclonal antibodies, including expression in engineered bacterial- and mammalian-based systems.

Arenavirus monoclonal antibodies and uses

The present invention includes methods of making, and compositions comprising, a uniformly lethal filovirus for outbred small mammals by mutation of the viral genome through serial passages in a small mammal, the method comprising the steps of: obtaining a filovirus strain from a human subject; passing the filovirus strain one or more times by intramuscular injection of one or more filovirus infected tissues into an inbred small mammal until uniform lethality is obtained; passing the filovirus strain in one or more human cell lines; passing the filovirus strain one or more times by intraperitoneal injection of one or more filovirus infected tissues into an outbred small mammal until uniform lethality is obtained; and isolating the uniformly lethal filovirus obtained thereby.

Variant angola marburg virus

The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.

Compositions and methods for silencing ebola virus gene expression

Compositions and methods for silencing Ebola virus gene expression

The present invention relates to genetic vaccines for stimulating cellular and humoral immune responses in humans and other hosts, and, in particular, relates to recombinant viruses that express heterologous antigens of pathogenic viruses, in single dose form.

Method of accelerated vaccination against Ebola viruses

The present invention provides siRNA molecules that target Filovirus gene expression and methods of using such siRNA molecules to silence Filovirus gene expression. The present invention also provides nucleic acid-lipid particles that target Filovirus gene expression comprising an siRNA that silences Filovirus gene expression, a cationic lipid, and a non-cationic lipid.

siRNA silencing of filovirus gene expression

Growing community of inventors

Albany, TX, United States of America

Thomas W Geisbert